These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 22290600

  • 1. The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001.
    De Angel RE, Conti CJ, Wheatley KE, Brenner AJ, Otto G, Degraffenried LA, Hursting SD.
    Mol Carcinog; 2013 Jun; 52(6):446-58. PubMed ID: 22290600
    [Abstract] [Full Text] [Related]

  • 2. Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity.
    Nogueira LM, Dunlap SM, Ford NA, Hursting SD.
    Endocr Relat Cancer; 2012 Feb; 19(1):57-68. PubMed ID: 22143497
    [Abstract] [Full Text] [Related]

  • 3. Effects of intermittent and chronic calorie restriction on mammalian target of rapamycin (mTOR) and IGF-I signaling pathways in mammary fat pad tissues and mammary tumors.
    Dogan S, Johannsen AC, Grande JP, Cleary MP.
    Nutr Cancer; 2011 Feb; 63(3):389-401. PubMed ID: 21462085
    [Abstract] [Full Text] [Related]

  • 4. IGF1 dependence of dietary energy balance effects on murine Met1 mammary tumor progression, epithelial-to-mesenchymal transition, and chemokine expression.
    Ford NA, Nunez NP, Holcomb VB, Hursting SD.
    Endocr Relat Cancer; 2013 Feb; 20(1):39-51. PubMed ID: 23152442
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues.
    Moore T, Beltran L, Carbajal S, Strom S, Traag J, Hursting SD, DiGiovanni J.
    Cancer Prev Res (Phila); 2008 Jun; 1(1):65-76. PubMed ID: 19138937
    [Abstract] [Full Text] [Related]

  • 7. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
    Macaskill EJ, Bartlett JM, Sabine VS, Faratian D, Renshaw L, White S, Campbell FM, Young O, Williams L, Thomas JS, Barber MD, Dixon JM.
    Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
    [Abstract] [Full Text] [Related]

  • 8. Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland.
    Torres-Arzayus MI, Yuan J, DellaGatta JL, Lane H, Kung AL, Brown M.
    Cancer Res; 2006 Dec 01; 66(23):11381-8. PubMed ID: 17145884
    [Abstract] [Full Text] [Related]

  • 9. Obesity-Associated Alterations in Inflammation, Epigenetics, and Mammary Tumor Growth Persist in Formerly Obese Mice.
    Rossi EL, de Angel RE, Bowers LW, Khatib SA, Smith LA, Van Buren E, Bhardwaj P, Giri D, Estecio MR, Troester MA, Hair BY, Kirk EL, Gong T, Shen J, Dannenberg AJ, Hursting SD.
    Cancer Prev Res (Phila); 2016 May 01; 9(5):339-48. PubMed ID: 26869351
    [Abstract] [Full Text] [Related]

  • 10. PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer.
    Riggio M, Polo ML, Blaustein M, Colman-Lerner A, Lüthy I, Lanari C, Novaro V.
    Carcinogenesis; 2012 Mar 01; 33(3):509-18. PubMed ID: 22180571
    [Abstract] [Full Text] [Related]

  • 11. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
    Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R, Modlin IM.
    Cancer; 2011 Sep 15; 117(18):4141-54. PubMed ID: 21387274
    [Abstract] [Full Text] [Related]

  • 12. Mammary cancer promotion by ovarian hormones involves IGFR/AKT/mTOR signaling.
    Arumugam A, Parada J, Rajkumar L.
    Steroids; 2012 Jun 15; 77(7):791-7. PubMed ID: 22465879
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.
    Clin Cancer Res; 2004 Dec 01; 10(23):8059-67. PubMed ID: 15585641
    [Abstract] [Full Text] [Related]

  • 14. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
    Liu H, Zang C, Schefe JH, Schwarzlose-Schwarck S, Regierer AC, Elstner E, Schulz CO, Scholz C, Possinger K, Eucker J.
    Anticancer Res; 2011 Sep 01; 31(9):2713-22. PubMed ID: 21868512
    [Abstract] [Full Text] [Related]

  • 15. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.
    Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, Testa JR.
    Cancer Res; 2007 Mar 15; 67(6):2408-13. PubMed ID: 17363557
    [Abstract] [Full Text] [Related]

  • 16. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
    Bago-Horvath Z, Sieghart W, Grusch M, Lackner A, Hayden H, Pirker C, Komina O, Węsierska-Gądek J, Haitel A, Filipits M, Berger W, Schmid K.
    Neuroendocrinology; 2012 Mar 15; 96(3):228-37. PubMed ID: 22378048
    [Abstract] [Full Text] [Related]

  • 17. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
    Zitzmann K, Rüden Jv, Brand S, Göke B, Lichtl J, Spöttl G, Auernhammer CJ.
    Cancer Lett; 2010 Sep 01; 295(1):100-9. PubMed ID: 20356670
    [Abstract] [Full Text] [Related]

  • 18. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
    Treeck O, Wackwitz B, Haus U, Ortmann O.
    Gynecol Oncol; 2006 Aug 01; 102(2):292-9. PubMed ID: 16443261
    [Abstract] [Full Text] [Related]

  • 19. Low-carbohydrate diet versus caloric restriction: effects on weight loss, hormones, and colon tumor growth in obese mice.
    Wheatley KE, Williams EA, Smith NC, Dillard A, Park EY, Nunez NP, Hursting SD, Lane MA.
    Nutr Cancer; 2008 Aug 01; 60(1):61-8. PubMed ID: 18444137
    [Abstract] [Full Text] [Related]

  • 20. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
    Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, Gorshtein A, Praiss M, Kendler E, Feinmesser R, Grossman AB, Shimon I.
    Mol Cell Endocrinol; 2010 Feb 05; 315(1-2):87-94. PubMed ID: 19815051
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.